Urine and blood protein matter more than a gene test for this chemo drug
Original title: MTHFR C677T genetic polymorphisms are not a decisive factor in delayed methotrexate excretion in central nervous system lymphoma patients.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This looked back at past patient records, not a new treatment test.
The short version
Two simple things mattered more than a gene test for this chemo drug.
What was studied. Doctors looked back at 213 rounds of high dose methotrexate in 98 people with central nervous system lymphoma. They checked what made the drug leave the body too slowly.
What they found. The drug cleared slowly in 66 rounds and normally in 147 rounds. Low blood protein and acidic urine were tied to slow clearing. The MTHFR C677T gene change was not clearly tied to it once other things were counted.
What this means, and what it doesn't
What it could mean: Doctors may focus on keeping urine less acidic and blood protein levels up. Cutting the drug dose just because of this gene may not be needed.
What it doesn't mean: This was a look back at old records at one hospital. It was not a test of a new treatment. It does not mean gene testing is useless for everyone. It is not a cure, and it does not change your care by itself. More studies are needed before care rules change.
Source: PubMed, July 27, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.